All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

China’s NMPA Accepts BLA for Zanidatamab in HER2+ Biliary Tract Cancer

June 10th 2024

China’s National Medical Products Administration has accepted the biologics license application for zanidatamab in second-line HER2+ biliary tract cancer.

FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC

June 10th 2024

The FDA has granted priority review to the supplemental NDA seeking the approval of osimertinib in EGFR-mutated stage III non–small cell lung cancer.

Braun Spotlights Novel Treatment Developments in RCC

June 10th 2024

David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances.

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

June 10th 2024

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

Factors for JAK Inhibitor Selection in Myelofibrosis in the First Line and Beyond

June 9th 2024

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

New Case Study Highlights Community Oncology Practices as Preferred Site of Service Over Hospitals and Academic Centers

June 9th 2024

A case study showed community oncology practices emerged as the preferred site of service for cancer treatment.

Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes

June 8th 2024

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

June 8th 2024

MammaPrint high 2 HR-positive/HER2-negative early-stage breast cancer exhibited a heightened immune active state.

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

June 7th 2024

Benjamin L. Maughan, MD, PharmD, dives into key studies in RCC regarding biomarkers and first-line treatments presented at the 2024 ASCO Annual Meeting

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

June 7th 2024

Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

June 7th 2024

Dostarlimab plus carboplatin and paclitaxel improved PFS and OS in dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

June 7th 2024

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Subcutaneous Pertuzumab/Trastuzumab Maintains Comparable Efficacy/Safety vs IV Formulations in HER2+ Breast Cancer

June 7th 2024

Long-term outcomes with subcutaneous pertuzumab/trastuzumab plus chemo were comparable to the IV combo in HER2+ early breast cancer.

Most Young Breast Cancer Survivors Can Have Children

June 7th 2024

Most young breast cancer survivors can go on to have children despite the effects of their lifesaving treatment, a new study shows.

Oncologic Supportive Care Is Absolutely Critical—But How Do We Define It?

June 7th 2024

Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.

Braun Highlights Advances in RCC Treatment Paradigm, Looks Towards Future

June 7th 2024

David A. Braun, MD, PhD, discusses the evolving treatment landscape of renal cell carcinoma.

FDA Approves Imetelstat for Low- to Intermediate-1–Risk MDS With Transfusion-Dependent Anemia

June 7th 2024

The FDA has approved imetelstat (Rytelo) for select patients with myelodysplastic syndrome and transfusion-dependent anemia.

Mirvetuximab Soravtansine Meets Primary End Point of PICCOLO Trial in FRα-High, Platinum-Sensitive Ovarian Cancer

June 6th 2024

Mirvetuximab soravtansine led to an ORR of 51.9% in heavily pretreated patients with FRα-positive, platinum-sensitive ovarian cancer.

Teclistamab Triplet Shows Manageable Safety, Early Efficacy in Transplant-Ineligible Myeloma

June 6th 2024

Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML

June 6th 2024

Eunice S. Wang, MD, discusses current unmet needs and efforts to move menin inhibitors into earlier lines of therapy in relapsed/refractory AML.